3.70
Cingulate Inc Aktie (CING) Neueste Nachrichten
Can Cingulate Inc. stock deliver consistent earnings growthMarket Volume Report & Risk Adjusted Swing Trade Ideas - newser.com
Will Cingulate Inc. stock gain from government policies2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
Backtesting results for Cingulate Inc. Equity Warrant trading strategiesInsider Selling & Stepwise Trade Execution Plans - newser.com
What institutional flow reveals about Cingulate Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
Will Cingulate Inc. stock remain a Wall Street favoriteTrade Signal Summary & Safe Entry Zone Identification - newser.com
Using portfolio simulators with Cingulate Inc. Equity Warrant includedTrade Entry Report & Entry Point Strategy Guides - newser.com
How Cingulate Inc. stock compares to industry benchmarksTrade Risk Assessment & High Conviction Buy Zone Alerts - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock bottoming outJuly 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success - TipRanks
How supply chain issues affect Cingulate Inc. stock2025 Investor Takeaways & Expert Verified Movement Alerts - newser.com
Why Cingulate Inc. stock could be next big winnerJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Does Cingulate Inc. fit your quant trading modelMarket Rally & Smart Investment Allocation Tips - newser.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review Retail Bets On Buyout Potential - Menafn.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - Asianet Newsable
Will Cingulate Inc. continue its uptrendJuly 2025 Earnings & Long-Term Safe Return Strategies - newser.com
FDA accepts Cingulate’s ADHD drug application, sets May 2026 target date - Investing.com Canada
What’s next for Cingulate Inc. stock priceJuly 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Cingulate receives target date for when it could receive FDA approval - The Business Journals
Cingulate Inc’s NDA for CTx-1301 Accepted by FDA - TipRanks
Cingulate announces FDA accepted for review the NDA for CTx-1301 - TipRanks
Cingulate Inc FDA Accepts NDA for CTx-1301 for ADHD - TradingView
FDA Accepts Cingulate’s New Drug Application for CTx-1301 - GlobeNewswire
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date - Yahoo Finance
Will Cingulate Inc. bounce back from current support2025 Retail Activity & Verified Entry Point Signals - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
How Cingulate Inc. Equity Warrant stock trades before earningsWatch List & Daily Market Momentum Tracking - newser.com
Is it too late to sell Cingulate Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - newser.com
Is Cingulate Inc a good long term investmentREITs Market Trends & Rapid Portfolio Strategies - earlytimes.in
Cingulate Inc. (NASDAQ:CING) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Is Cingulate Inc. stock entering bullish territoryCEO Change & Smart Money Movement Alerts - newser.com
Analyzing drawdowns of Cingulate Inc. Equity Warrant with statistical tools2025 Year in Review & Stock Timing and Entry Methods - newser.com
Market reaction to Cingulate Inc.’s recent newsDividend Hike & Consistent Income Trade Ideas - newser.com
Is Cingulate Inc. a candidate for recovery playInsider Selling & Weekly Chart Analysis and Guides - newser.com
Cingulate Inc. stock retracement – recovery analysisTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):